哪种治疗方式为糖尿病视网膜病变提供了最好的结果? 一个系统的审查和网络元分析
Kai-Yang Chen1, Hoi-Chun Chan2, Chi-Ming Chan3
1School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Diabetes research and clinical practice
|July 23, 2025
概括
与泛视网膜光凝固 (PRP) 相比,抗血管内皮生长因子 (anti-VEGF) 疗法显著改善视力,并减少糖尿病视网膜病变 (DR) 患者的视网膜厚度. 抗VEGF治疗也显示出更好的安全性,支持它们作为DR的第一线治疗.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 医疗干预 医疗干预
背景情况:
- 糖尿病视网膜病变 (DR) 是全球可预防失明的主要原因之一.
- 增殖性糖尿病视网膜病变 (PDR) 和糖尿病黄斑 (DME) 是DR的视力威胁并发症.
- 全网膜光凝 (PRP) 是一种传统的治疗方法,但抗血管内皮生长因子 (anti-VEGF) 疗法提供了替代方案.
研究的目的:
- 为了比较抗VEGF药物,PRP和对DR的组合疗法的疗效和安全性.
- 评估DR患者接受不同治疗的视觉和解剖结果.
- 通过网络元分析,综合随机对照试验 (RCT) 的证据.
主要方法:
- 系统地搜索主要数据库和试验注册表的文献,直到2025年2月.
- 包括对抗VEGF药物 (Ranibizumab,Aflibercept,Bevacizumab),PRP或DR患者的组合治疗进行比较的RCT.
- 贝叶斯网络元分析以评估最佳校正的视敏度 (BCVA),中枢视网膜厚度 (CRT),新血管化和不良事件.
主要成果:
- 抗VEGF疗法在12个月后显示出比PRP更好的BCVA改善 (+3.39字母) 和更大的CRT减少 (-24.50微米).
- 与抗VEGF药物 (OR:6.15) 使用时,观察到更高的新血管化回归率.
- 组合疗法提供了额外的CRT降低,而抗VEGF剂的不良事件比PRP少.
结论:
- 抗VEGF疗法比PRP更有效地改善视力敏度和减少DR的斑点厚度.
- 与PRP相比,抗VEGF药物具有更高的安全性,不良事件风险较低.
- 这些发现支持抗VEGF疗法作为视力威胁性DR的首选一线治疗方法.
相关概念视频
01:27Open Angle Glaucoma: Treatment
577
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
577
01:15Diabetes: Management and Pharmacotherapy
399
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
399